在转移性乳腺癌中的elacestrant:当前的进展和未来的前景
Taha Koray Sahin1, Binura Makasheva1, Deniz Can Guven1
1Department of Medical Oncology, Hacettepe University, Ankara, Turkey.
Expert review of anticancer therapy
|December 29, 2025
概括
伊拉克斯特兰为先进的乳腺癌提供了一种新的口服治疗方法,这种癌症对内分泌疗法有抗性,特别是当ESR1突变存在时. 这种选择性雌激素受体降解剂改善了转移性疾病患者的结果和耐受性.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素受体阳性,HER2阴性晚期乳腺癌是常见的,并具有挑战性治疗.
- 内分泌治疗耐药性,通常是由于ESR1突变,限制了治疗的有效性.
- 需要新的口服内分泌药物来提高功效,生物可用性和耐受性.
研究的目的:
- 评估elacestrant,一个口服选择性雌激素受体降解剂,用于内分泌抵抗性乳腺癌.
- 讨论elacestrant的药理学,抗瘤活性和临床结果.
- 探索elacestrant在组合疗法和早期疾病阶段的潜力.
主要方法:
- 对elacestrant的特性和临床数据进行了全面的审查.
- 分析其在管理ESR1-突变转移性转移性乳腺癌中的作用.
- 讨论正在进行的研究和未来的方向.
主要成果:
- 伊拉克斯特兰在ESR1突变患者中提供持久的雌激素受体抑制和良好的耐受性.
- 与CDK4/6和PI3K-AKT-TOR抑制剂的组合疗法显示出有前途的结果.
- 液体活检和分子监测有助于个性化治疗适应.
结论:
- 伊拉克斯特兰是内分泌抵抗性转移性乳腺癌的关键选择,特别是ESR1突变.
- 个性化内分泌疗法正在通过分子精度和临床实用性进步.
- 未来的策略包括基于分子分析的组合疗法和动态治疗调整.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:30Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:38Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K